Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Intravenous COTI-2 In Combination With Doxil(R) Is More Effective Than Treatment With Doxil Alone In An Animal Model Of Human Ovarian Cancer
Critical Outcome Technologies Inc. (TSX VENTURE:COT), announced positive results today from combination agent animal experiments carried out at a prominent American cancer research facility. The results provide strong supportive evidence for the continued evaluation of COTI-2 in combination with conventional single agent therapy for the treatment of ovarian cancer:

In Rare Disorder, A Familiar Protein Disrupts Gene Function
An international team of scientists studying a rare genetic disease discovered that a bundle of proteins with the long-established function of keeping chromosomes together also plays an important role in regulating genes in humans.
News of the day
AVMA House Of Delegates Welcomes New President; Takes Action To Combat Recession And Uphold Animal Welfare Policy
At the 146th Annual Convention of the American Veterinary Medical Association (AVMA), association leaders welcomed a new president and took action on animal welfare and antimicrobial policies as well as cost cutting measures.
Nutrition

New MedPredict Report Reveals Top Alzheimer's Experts' Insights On Diagnostics And Treatments In Development Pipeline

MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report entitled "Thought Leader Insight & Analysis: Alzheimer"s Disease," designed to provide critical strategic insight for pharma and biotech companies with a stake in the market for diagnostics and treatments in this disease area. MedPredict interviewed renowned Alzheimer"s disease thought leaders to identify the most promising candidates in clinical development, as well as explore unmet needs. Interviews for this report were conducted following the 2009 American Academy of Neurology (AAN) conference. "In this report, our panel of experts describes the clinical progress of the most interesting therapeutic and diagnostic candidates in the pipeline," according to Jeff Berk, MedPredict"s president and lead author of this report. "The panel covers active and passive immunologic approaches that hold promise in prevention of Alzheimer"s disease and treatment at the earliest stages of dementia." "The panelists rank the most promising small molecules and antibodies that are targeting amyloid and plaques, offering their opinions on gamma-secretase inhibitors and modulators, beta-secretase inhibitors, Tau phosphorylation inhibitors, cardiovascular agents, anti-amyloids and aggregation inhibitors, histone deacetylases (HDACs), SIRT-1, metal chelators and drugs like Dimebon, specifically designed to enhance mental function," says Berk. "They also update the progress coming out of ADNI, the Alzheimer"s Disease Neuroimaging Initiative, and describe how some amazing diagnostic tools have now been incorporated into the pivotal trials of these exciting therapeutics." Companies/partnerships discussed in this report: Abbott, Allon, Astellas/CoMentis, AstraZeneca/Banner, AstraZeneca/Takeda, AstraZeneca/Targacept, Avid, Baxter, Bayer-Schering/Avid Radiopharmaceuticals, Boehringer Ingelheim/Ablynx, Bristol-Myers Squibb, Elan/Transition Therapeutics/AZ, Elan/Wyeth, Envivo, Eisai, Forest/Merz/Lundbeck/Daiichi-Sankyo, GE Healthcare, GlaxoSmithKline, Lilly, Lilly/Elan, Link, Myriad, Novartis, Oligomerix, Pfizer, Pfizer/Medivation, Prana, Roche/Memory, Satori, TauRx, TauTaTis, Transtech, and Wyeth. About MedPredict MedPredict maintains a proprietary database of over 1,000 global physician thought leaders. Based on primary interviews with these thought leaders, MedPredict publishes periodic therapeutic area reports to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and presentations, as well as clinical, regulatory and marketing activity. MedPredict


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009